Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 75.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 67,231 shares of the company's stock after selling 203,292 shares during the quarter. Assenagon Asset Management S.A. owned 0.13% of Cardiff Oncology worth $292,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Cardiff Oncology by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 928,232 shares of the company's stock valued at $2,479,000 after buying an additional 17,557 shares during the period. State Street Corp raised its stake in shares of Cardiff Oncology by 3.4% in the third quarter. State Street Corp now owns 832,652 shares of the company's stock valued at $2,223,000 after acquiring an additional 27,628 shares in the last quarter. MAI Capital Management boosted its holdings in Cardiff Oncology by 0.7% in the third quarter. MAI Capital Management now owns 663,363 shares of the company's stock valued at $1,771,000 after purchasing an additional 4,569 shares during the period. GSA Capital Partners LLP grew its stake in Cardiff Oncology by 432.7% during the 3rd quarter. GSA Capital Partners LLP now owns 186,650 shares of the company's stock worth $498,000 after purchasing an additional 151,613 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Cardiff Oncology by 82.9% during the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company's stock worth $350,000 after purchasing an additional 71,390 shares during the period. Institutional investors and hedge funds own 16.29% of the company's stock.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace purchased 350,115 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the purchase, the director now directly owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.80% of the company's stock.

Cardiff Oncology Stock Down 2.6 %

Cardiff Oncology stock traded down $0.09 during midday trading on Friday, reaching $3.41. The company's stock had a trading volume of 665,399 shares, compared to its average volume of 987,688. The company has a market cap of $174.35 million, a P/E ratio of -3.63 and a beta of 1.76. The business has a 50-day simple moving average of $3.49 and a 200-day simple moving average of $2.90. Cardiff Oncology, Inc. has a fifty-two week low of $1.44 and a fifty-two week high of $6.42.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02. The firm had revenue of $0.17 million during the quarter, compared to analysts' expectations of $0.13 million. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. As a group, equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

CRDF has been the subject of several recent research reports. Piper Sandler lifted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. HC Wainwright decreased their price target on shares of Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Friday, November 8th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.